Yuan-yuan JIN, Jun-ling ZHUANG. Autologous Stem Cell Transplantation for Multiple Myeloma in the Era of Novel Medicines[J]. Medical Journal of Peking Union Medical College Hospital, 2018, 9(3): 219-223. doi: 10.3969/j.issn.1674-9081.2018.03.006
Citation: Yuan-yuan JIN, Jun-ling ZHUANG. Autologous Stem Cell Transplantation for Multiple Myeloma in the Era of Novel Medicines[J]. Medical Journal of Peking Union Medical College Hospital, 2018, 9(3): 219-223. doi: 10.3969/j.issn.1674-9081.2018.03.006

Autologous Stem Cell Transplantation for Multiple Myeloma in the Era of Novel Medicines

doi: 10.3969/j.issn.1674-9081.2018.03.006
More Information
  • Corresponding author: ZHUANG Jun-ling Tel:010-69155027, Email: zhuangjunling@pumch.cn
  • Received Date: 2017-07-13
  • Publish Date: 2018-05-30
  • The overall survival(OS) in patients with multiple myeloma (MM) has been prolonged from 3 years to 8-10 years during the past 20 years, which benefits from the broad use of novel agents including proteasome inhibitors and immune modulatory drugs. Even in the era of novel medicines, high-dose melphalan followed by autologous stem cell transplantation (ASCT) is the standard treatment for transplant candidates of newly diagnosed MM. ASCT significantly further improves the post-transplant response rate and the proportion of negative minimal residual disease, as well as leading to better progression-free survival. Nevertheless, the effect of ASCT on OS was not consistent among different clinical trials, which was probably related to different strategies after relapse. As other novel methods including monoclonal antibodies and immune therapies are being developed, more alternatives will be considered. Therefore, ASCT is still the front-line consolidation regimen for transplant candidates with MM.
  • loading
  • [1] Anderson KC. Progress and paradigms in multiple myeloma[J]. Clin Cancer Res, 2016, 22:5419-5427. doi:  10.1158/1078-0432.CCR-16-0625
    [2] McElwain TJ, Powles RL. High-dose intravenous melphalan for plasma-cell leukaemia and myeloma[J]. Lancet, 1983, 2:822-824. http://onlinelibrary.wiley.com/resolve/reference/PMED?id=6137651
    [3] Attal M, Harousseau JL, Stoppa AM, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome[J]. N Engl J Med, 1996, 335:91-97. doi:  10.1056/NEJM199607113350204
    [4] Child JA, Morgan GJ, Davies FE, et al. Medical research council adult leukaemia working party. High-dose chemo-therapy with hematopoietic stem-cell rescue for multiple myeloma[J]. N Engl J Med, 2003, 348:1875-1883. doi:  10.1056/NEJMoa022340
    [5] Martinez-Lopez J, Blade J, Mateos MV, et al. Long-term prognostic significance of response in multiple myeloma after stem cell transplantation[J]. Blood, 2011, 118:529-534. http://europepmc.org/abstract/MED/21482708
    [6] Attal M, Harousseau JL, Facon T, et al. Single versus double autologous stem-cell transplantation for multiple myeloma[J]. N Engl J Med, 2003, 349:2495-2502. doi:  10.1056/NEJMoa032290
    [7] Bladé J, Rosiñol L, Sureda A, et al. High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy:long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA[J]. Blood, 2005, 106:3755-3759. http://www.tandfonline.com/servlet/linkout?suffix=CIT0008&dbid=16&doi=10.1517%2F14656566.7.2.195&key=10.1182%2Fblood-2005-03-1301
    [8] Roussel M, Lauwers-Cances V, Robillard N, et al. Front-line transplantation program with lenalidomide, bortezomib, and dexamethasone combination as induction and consolidation followed by lenalidomide maintenance in patients with multiple myeloma:a phase Ⅱ study by the Intergroupe Francophone du Myélome[J]. J Clin Oncol, 2014, 32:2712-2717. doi:  10.1200/JCO.2013.54.8164
    [9] Koreth J, Cutler CS, Djulbegovic B, et al. High-dose therapy with single autologous transplantation versus chemotherapy for newly diagnosed multiple myeloma:a systematic review and meta-analysis of randomized controlled trials[J]. Biol Blood Marrow Transplan, 2007, 13:183-196. doi:  10.1016/j.bbmt.2006.09.010
    [10] Sonneveld P, Goldschmidt H, Rosiñol L, et al. Bortezomib-based versus nonbortezomib-based induction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma:a meta-analysis of phase Ⅲ randomized, controlled trials[J]. J Clin Oncol, 2013, 31:3279-3287. doi:  10.1200/JCO.2012.48.4626
    [11] Harousseau JL, Attal M, Avet-Loiseau H, et al. Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma:results of the IFM 2005-01 phase Ⅲ trial[J]. J Clin Oncol, 2010, 28:4621-4629. doi:  10.1200/JCO.2009.27.9158
    [12] Sonneveld P, Schmidt-Wolf IG, van der Holt B, et al. Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma:results of the randomized phase Ⅲ HOVON-65/GMMG-HD4 trial[J]. J Clin Oncol, 2012, 30:2946-2955. doi:  10.1200/JCO.2011.39.6820
    [13] Rosiñol L, Oriol A, Teruel AI, et al. Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma:a randomized phase 3 PETHEMA/GEM study[J]. Blood, 2012, 120:1589-1596. http://www.tandfonline.com/servlet/linkout?suffix=CIT0047&dbid=16&doi=10.1080%2F17474086.2018.1437345&key=10.1182%2Fblood-2012-02-408922
    [14] Cavo M, Tacchetti P, Patriarca F, et al. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma:a randomised phase 3 study[J]. Lancet, 2010, 376:2075-2085. doi:  10.1016/S0140-6736(10)61424-9
    [15] Palumbo A, Cavallo F, Gay F, et al. Autologous transplantation and maintenance therapy in multiple myeloma[J]. N Engl J Med, 2014, 371:895-905. doi:  10.1056/NEJMoa1402888
    [16] Richardson PG, Weller E, Lonial S, et al. Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma[J]. Blood, 2010, 116:679-686. http://europepmc.org/articles/PMC3324254/
    [17] Attal M, Lauwers-Cances V, Hulin C, et al. Lenalidomide, Bortezomib, and Dexamethasone with transplantation for myeloma[J]. N Engl J Med, 2017, 376:1311-1320. doi:  10.1056/NEJMoa1611750
    [18] Attal M, Harousseau JL, Leyvraz S, et al. Maintenance the-rapy with thalidomide improves survival in patients with multiple myeloma[J]. Blood, 2006, 108:3289-3294. http://europepmc.org/abstract/MED/16873668
    [19] Spencer A, Prince HM, Roberts AW, et al. Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure[J]. J Clin Oncol, 2009, 27:1788-1793. doi:  10.1200/JCO.2008.18.8573
    [20] Barlogie B, Tricot G, Anaissie E, et al. Thalidomide and hematopoietic-cell transplantation for multiple myeloma[J]. N Engl J Med, 2006, 354:1021-1030. doi:  10.1056/NEJMoa053583
    [21] Barlogie B, Pineda-Roman M, van Rhee F, et al. Thalido-mide arm of Total Therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities[J]. Blood, 2008, 112:3115-3121. http://www.ncbi.nlm.nih.gov/pubmed/18492953
    [22] Lokhorst HM, van der Holt B, Zweegman S, et al. A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma[J]. Blood, 2010, 115:1113-1120. doi:  10.1182/blood-2009-05-222539
    [23] Morgan GJ, Gregory WM, Davies FE, et al. The role of maintenance thalidomide therapy in multiple myeloma:MRC Myeloma IX results and meta-analysis[J]. Blood, 2012, 119:7-15. doi:  10.1182/blood-2011-06-357038
    [24] Attal M, Lauwers-Cances V, Marit G, et al. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma[J]. N Engl J Med, 2012, 366:1782-1791. doi:  10.1056/NEJMoa1114138
    [25] McCarthy PL, Owzar K, Hofmeister CC, et al. Lenalidomide after stem-cell transplantation for multiple myeloma[J]. N Engl J Med, 2012, 366:1770-1781. doi:  10.1056/NEJMoa1114083
    [26] Michaelis LC, Saad A, Zhong X, et al. Salvage second hematopoietic cell transplantation in myeloma[J]. Biol Blood Marrow Transplant, 2013, 19:760-766. doi:  10.1016/j.bbmt.2013.01.004
    [27] Kumar SK, Lacy MQ, Dispenzieri A, et al. Early versus delayed autologous transplantation after immunomodulatory agents-based induction therapy in patients with newly diagnosed multiple myeloma[J]. Cancer, 2012, 118:1585-1592. doi:  10.1002/cncr.26422
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Article Metrics

    Article views (334) PDF downloads(255) Cited by()
    Proportional views
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return